KIND T Cells in H3.3K27M-positive Diffuse Midline Gliomas

Phase 1, open-label, single-arm trial of Autologous Anti-H3.3K27M TCR-expressing T-cells in diffuse midline glioma (DMG), sponsored by University of California, San Francisco. Primary endpoints: Frequency and severity of adverse events at 28 days and Percent of successfully manufactured KIND T cells at 24 months. Started Jul 2023; status: terminated.